Pulmonary (lung) rehabilitation nearly halves the odds of people with chronic obstructive pulmonary disease (COPD) experiencing an exacerbation, and it also cuts the risk of dying by about one-third, a study in Korea found. The study, “Pulmonary Rehabilitation Is Associated With Decreased Exacerbation and Mortality in Patients With…
News
Scientists at NextCure have developed a monoclonal antibody targeting the protein VSTM-1, which the company hopes to develop as a treatment for inflammatory lung disorders such as chronic obstructive pulmonary disease (COPD). “We believe we have a real opportunity to change the standard of care in…
Yupelri (revefenacin) is not superior to Spiriva (tiotropium) at improving lung function in adults with severe chronic obstructive pulmonary disease (COPD), according to data from a Phase 4 clinical trial. The head-to-head study, called PIFR-2 (NCT05165485) and sponsored by Yupelri’s co-developers Theravance Biopharma and…
Two international Phase 3 clinical trials testing the investigational antibody itepekimab in people with chronic obstructive pulmonary disease (COPD) are continuing to enroll patients — specifically, former smokers — at hundreds of centers worldwide, with several new sites recently opened in the U.S. All of the new sites are…
The number of people worldwide with chronic obstructive pulmonary disease (COPD) is predicted to increase by 23% in three decades, amounting to nearly 600 million patients by 2050, according to a new study. The largest increase, by nearly 50%, is projected to be among women and people living in…
Treatment with Dupixent (dupilumab) — approved in the U.S. for five inflammatory conditions, to date — once again resulted in significantly fewer exacerbations, or periods of sudden symptom worsening, among people with moderate to severe chronic obstructive pulmonary disease (COPD) in the second of two similarly designed Phase 3…
Long-term treatment with Olympus’ Spiration Valve System (SVS) safely led to sustained improvements in lung function — and in life quality — among people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). That’s according to two-year follow-up data from the EMPROVE trial, which had tested…
Treatment with the anti-inflammatory medication eblasakimab opened the airways of lung samples from people with chronic obstructive pulmonary disorder (COPD) in laboratory experiments. The findings were shared by Aslan Pharmaceuticals, the company that’s developing eblasakimab, in an oral presentation at the Dermatology Drug Development Summit, held recently in…
The American Lung Association has launched an initiative that has as its goal improving the quality of life of people who’ve been living with chronic obstructive pulmonary disease (COPD) for at least a decade. The “COPD for…
The U.S. Food and Drug Administration (FDA) has approved ReAlta Life Sciences’ request to launch a Phase 2 clinical trial testing its experimental anti-inflammatory therapy RLS-0071 in people with chronic obstructive pulmonary disease (COPD) who are experiencing disease exacerbations. Exacerbations, or disease flare-ups, may occur several times per year…
Recent Posts
- Living with COPD doesn’t mean you can’t age with grace December 9, 2025
- COPD experimental therapy moves into new phase after positive results December 3, 2025
- Having structure in my recovery routine helps me stay grounded November 25, 2025
- The comfort food that diagnosed my dangerous drift from health balance November 18, 2025
- I’m bringing my cheerleader’s pompoms to the long game of COPD November 11, 2025
- American Lung Association invests $22M in lung disease research November 5, 2025
- Weighty matters: Why 140 pounds no longer haunts me November 4, 2025
- The ache of limitation and the grace of persistence in life with COPD October 28, 2025
- Focusing on education, action for this year’s COPD Awareness Month October 27, 2025
- Learning firsthand about the risk of shingles with COPD October 21, 2025